Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation

Among the more than 100 published cases of Philadelphia chromosome–positive chronic myelogenous leukemia (Ph+ CML) investigated for the 1849G > T mutation of the Janus kinase 2 (JAK2V617F),[1][1]no mutated cases have been found so far.[2][2],[3][3] Selected patients with Ph+ CML with marked